TRIM33 and cancer: In one study with 10-year follow-up, all the detected malignancy cases in the anti-TIF1γ+ cohort occurred between 3 years prior to and 2.5 years after DM onset, whereas cancers were detected in the following 7.5 years in anti-TIF1γ- patients (34).